# US 2013/0261072 A1 · Oligomer conjugates of heteropentacyclic nucleosides

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0261072 A1
- Document ID: US20130261072A1
- Status: Published application
- Kind: A1
- Application number: 13/897,116
- Filed: 2013-05-17
- Published: 2013-10-03
- Earliest claimed: 2008-02-22
- Assignees: Nektar Therapeutics
- Applicants: Nektar Therapeutics
- Inventors: Bo-Liang Deng; Timothy A. Riley; Jennifer Riggs-Sauthier
- Web page: https://patentgrep.com/patent/US20130261072A1

## CPC

- A61K 47/60: the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
- A61K 31/7056: containing five-membered rings with nitrogen as a ring hetero atom
- A61P 31/12: Antivirals
- C07H 19/056: Triazole or tetrazole radicals
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13)

## Abstract

The invention provides small molecule drugs that are chemically modified by covalent attachment of a water-soluble oligomer

## Claims

### Claim at position 1

-24. (canceled)

### Claim 25

A method comprising administering to a subject a compound having the following structure:
wherein:
R2 is hydrogen or hydroxyl;
R3 is hydroxyl when R2 is hydrogen and R3 is hydrogen when R2 is hydroxyl;
(a) is two;
X is an amide linkage; and
each POLY is independently a water-soluble, non-peptidic oligomer, and 5’-phosphates and 3′,5′-cyclic phosphates thereof and ammonium and alkali metal salts of each of the 5′-phosphates and 3′,5′-cyclic phosphates.

### Claim 26 (depends on 25)

The method of claim 25, wherein the weight average molecular weight of each water-soluble, non-peptidic oligomer is less than 400 Daltons.

### Claim 27 (depends on 25)

The method of claim 25, wherein each water-soluble, non-peptidic oligomer is a poly(alkylene oxide).

### Claim 28 (depends on 27)

The method of claim 27, wherein each poly(alkylene oxide) is a poly(ethylene oxide).

### Claim 29 (depends on 28)

The method of claim 28, wherein the poly(ethylene oxide) oligomer has a number of repeating monomers in the range of from 1 to 30.

### Claim 30 (depends on 29)

The method of claim 29, wherein the water-soluble, non-peptidic oligomer has a number of repeating monomers in the range of from 1 to 10.

### Claim 31 (depends on 27)

The method of claim 27, wherein the poly(alkylene oxide) includes an alkoxy or hydroxy end-capping moiety.

### Claim 32 (depends on 25)

The method of claim 25, wherein the compound is administered as part of a composition comprising (i) the compound of claim 25, and (ii) a pharmaceutically acceptable excipient.

### Claim 33 (depends on 25)

The method of claim 25, wherein a dosage form comprising the compound of claim 25 is administered.

### Claim 34 (depends on 25)

The method of claim 25, wherein the compound is administered orally.

### Claim 35 (depends on 32)

The method of claim 32, wherein the composition is administered orally.

### Claim 36 (depends on 25)

The method of claim 25, wherein the amount of compound administered is in the range of 0.01mg to 750mg.

### Claim 37 (depends on 25)

The method of claim 25, wherein the compound is selected from a compound of the formula
wherein for each occurrence, n is an integer from 1 to 15; and 5′-phosphates and 3′,5′-cyclic phosphates thereof and ammonium and alkali metal salts of each of the 5′-phosphates and 3′,5′-cyclic phosphates.

### Claim 38 (depends on 37)

The method of claim 37, wherein for each occurrence, n is an integer from 1 to 10.

### Claim 39 (depends on 38)

The method of claim 38, wherein for each occurrence, n is 5.

### Claim 40 (depends on 37)

The method of claim 37, wherein the compound is administered as part of a composition comprising (i) the compound of claim 37, and (ii) a pharmaceutically acceptable excipient.

### Claim 41 (depends on 37)

The method of claim 37, wherein the compound is administered orally.

### Claim 42 (depends on 40)

The method of claim 40, wherein the compound is administered orally.

### Claim 43 (depends on 37)

The method of claim 37, wherein the amount of compound administered is in the range of 0.01 mg to 750mg.
